TD Bank (NYSE: TD) discloses 5.2% ownership of PTC Therapeutics (PTCT) shares
Rhea-AI Filing Summary
The Toronto-Dominion Bank has reported a significant ownership stake in PTC Therapeutics, Inc. The bank beneficially owns 4,138,215 shares of PTC Therapeutics common stock, representing 5.2% of the outstanding class as of 12/31/2025.
TD Bank reports sole power to vote and dispose of all 4,138,215 shares, with no shared voting or dispositive power. The bank states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of PTC Therapeutics (PTCT) does The Toronto-Dominion Bank own?
The Toronto-Dominion Bank owns 5.2% of PTC Therapeutics’ common stock. This corresponds to 4,138,215 shares of common stock as of December 31, 2025, giving the bank a reportable stake above the 5% regulatory disclosure threshold.
Why did The Toronto-Dominion Bank file a Schedule 13G for PTC Therapeutics (PTCT)?
The bank filed Schedule 13G because it beneficially owns more than 5% of PTCT common stock. It certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of PTC Therapeutics.
Is The Toronto-Dominion Bank seeking to influence control of PTC Therapeutics (PTCT)?
No. The filing states the PTCT shares were acquired and are held in the ordinary course of business and were not acquired, and are not held, for the purpose of changing or influencing the control of PTC Therapeutics in any way.
What type of reporting person is The Toronto-Dominion Bank in the PTCT Schedule 13G?
The Toronto-Dominion Bank is identified as a bank reporting person. It is organized under Canada (federal level) and files under the Schedule 13G framework applicable to institutions, disclosing its beneficial ownership position in PTC Therapeutics common stock.